Showing posts with label BRCA1. Show all posts
Showing posts with label BRCA1. Show all posts

Tuesday, December 25, 2012

Many have ovary surgery even with negative gene test


Many have ovary surgery even with negative gene test

Dec 18, 2012

Many women who test negative for gene mutations that heighten the risk of ovarian cancer still get their ovaries removed despite a lack of evidence that it reduces the risk of dying, says a new study.

"A higher number than expected went through with the surgery, and it probably has to do with doctors in the community not having enough information on their patients' risk levels," said Dr. Gabriel Mannis, the study's lead author.

According to Mannis and his colleagues, who published their study in the Archives of Internal Medicine on Monday, the average woman's risk of developing ovarian cancer is about 2 percent, but women with BRCA1 and BRCA2 gene mutations have a 40 percent and 20 percent risk, respectively.

For women that test positive for the gene mutations, the American Congress of Obstetricians and Gynecologists (ACOG) says, if they choose to have their ovaries removed, it should be when they are done having children and near 40 years old.

There are no guidelines, however, on ovary removal and screening for women whose blood tests don't show the gene mutations but who may still be at an increased risk of cancer based on their family's medical history.
"We don't have a clear sense of what their risk level is, or what the role of screening should be," said Mannis, of the division of oncology at the University of California, San Francisco.

For the new study, the researchers surveyed women at two hospitals about 4 years after they were tested for the gene mutations to see if they decided to be screened or have their ovaries removed.

Of 1,077 women surveyed, about 19 percent tested positive for a BRCA mutation, about 10 percent had no mutation, and the rest had unclear results.

The researchers found that about 70 percent of the women who tested positive for a mutation had their ovaries removed by the time they took the survey.

But, despite a lack of evidence that they should have their ovaries removed, about 12 percent of the women with unclear results still had the surgery.

Ovarian cancer screening

The researchers also found that despite the U.S. Preventive Services Task Force recommending against screening for ovarian cancer in women without the gene mutations, about 20 percent of women whose test results didn't clearly show the mutations still ended up getting screened in the year before taking the survey.
In a previously published study, women screened annually for ovarian cancer were no less likely to die from the disease than those who didn't get regular screening.

Aside from not being shown to help, the tests are also imperfect, said Dr. Jed Delmore, chair the Gynecologic Oncology Sub-committee for ACOG.

"I can simply say that as of today we don't have a good screening," said Delmore, of the University of Kansas School of Medicine in Wichita.

"At this point if doctors are going to proceed with screening in this group of women, there needs to be a conversation that we don't really know if this will prevent you from dying sooner of ovarian cancer or that it may come back as a false positive," said Mannis.

In that previous study, about one in ten screened women had a false positive result, and of those a third had one or both ovaries removed.

That means some women had both ovaries removed even though they were not at an increased risk for cancer, which needlessly put them in danger of a complication and forced them into menopause.
Plus, the removing an ovary can cost over $3,000.
Delmore told Reuters Health that it seems like an intermediate ground has been reached with a majority of BRCA-positive women having surgery to reduce their risk, and fewer BRCA-negative women having it.
He agreed with Mannis that doctors need to be honest with their patients about the limitations of today's screenings and treatments.

"We have pretty solid information for women who are BRCA positive and clearly BRCA negative," he said. "It's just that group in the middle."

Mannis told Reuters Health that the next step would be to identify that group's risk levels, but both he and Delmore said that won't be easy.


Fox News

Thursday, December 20, 2012

Scientists discover gene linked to breast and ovarian cancer


Scientists discover gene linked to breast and ovarian cancer


17 December 2012

A team of researchers led by the Institute of Cancer Research, London, have found that rare mutations in a gene called PPM1D are linked to an increased risk of breast and ovarian cancer. The mutations are not inherited, and the discovery potentially reveals a new mechanism of cancer development.

The study suggests that around one in five women with PPM1D mutations will develop breast or ovarian cancer in the course of their lifetime, almost double the breast cancer risk and more than ten times the ovarian cancer risk of women in the general population. The discovery could have implications for genetic testing and targeted prevention, in particular for ovarian cancer, which is often diagnosed at an advanced stage.

The team analysed 507 genes involved in DNA repair in 1150 women with breast or ovarian cancer, identifying PPM1D gene mutations in five women. They then sequenced the PPM1D gene in 7781 women with breast or ovarian cancer and 5861 people from the general population.

There were 25 faults in the PPM1D gene in women with cancer and only one in the general population, a highly statistically significant difference.

The study found that the mutated genes were not passed down from parent to child and were not present in every cell. Even more surprisingly, there were no PPM1D mutations in the cancer cells or in the normal breast or ovarian cells; they were found only in blood cells. The findings suggest that PPM1D works in a completely different way to other genes known to increase the risk of breast and ovarian cancer, such as BRCA1 and BRCA2, potentially highlighting a new cancer-causing mechanism.

The team found that the mutations made the molecule that is produced from the PPM1D gene shorter than usual. Such truncating mutations are usually thought to cause a loss of function; however, the team were surprised to find that in this case the PPM1D mutations seem to make it more active.

Study leader Professor Nazneen Rahman, head of genetics at the Institute of Cancer Research (ICR) and head of the cancer genetics clinical unit at the Royal Marsden NHS Foundation Trust, said: "This is one of our most interesting and exciting discoveries.
"At every stage the results were different from the accepted theories. We don't yet know exactly how PPM1D mutations are linked to breast and ovarian cancer, but this finding is stimulating radical new thoughts about the way genes and cancer can be related."

"The results could also be useful in the clinic, particularly for ovarian cancer, which is often diagnosed at an advanced stage. If a woman knew she carried a PPM1D mutation and had a one in five chance of developing ovarian cancer, she might consider keyhole surgery to remove her ovaries after completing her family."

Professor Alan Ashworth, chief executive of The Institute of Cancer Research and one of the study researchers, said: "This discovery really does turn conventional wisdom about the way genetic mutations can lead to cancer on its head. We are likely to gain many valuable insights into how cancers can occur as we continue to unravel this puzzle."

New genetic sequencing technologies that allow much deeper analysis of genes were crucial to enable the team to make the link between the PPM1D mutations and cancer. The discovery that the mutations were only present in some cells, a so-called mosaic pattern, would have been extremely difficult to detect with older sequencing methods.

It is possible that similar mosaic mutations in other genes, and in patients with other types of cancer, will emerge as more research groups are now using these deep sequencing techniques, the authors say.

Dr Michael Dunn, head of molecular and physiological sciences at the Wellcome Trust, said: "This study is an fantastic example of the power of next-generation sequencing to discover new cancer predisposing genes, offering opportunities for better diagnosis. The discovery also opens up a very exciting new avenue of research in the study of cancer development."

WelcomeTrust

Thursday, October 18, 2012

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast andovarian cancer.


BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast andovarian cancer.


Oct 2012

Source

Cancer Epigenetics and Biology Program; Bellvitge Biomedical Research Institute; Barcelona, Catalonia Spain.

Abstract


Germline mutations in the BRCA1 or BRCA2 genes are associated with an increased risk of breast and ovarian cancer development. Both genes are involved in DNA repair, and tumors harboring genetic defects in them are thought to be more sensitive to DNA-damaging agents used in chemotherapy. However, as only a minority of breast and ovarian cancer patients carry BRCA1 or BRCA2 mutations, few patients are likely to benefit from these pharmacogenetic biomarkers. Herein, we show that, in cancer cell lines and xenografted tumors, BRCA1 CpG island promoter hypermethylation-associated silencing also predicts enhanced sensitivity to platinum-derived drugs to the same extent as BRCA1 mutations. Most importantly, BRCA1 hypermethylation proves to be a predictor of longer time to relapse and improved overall survival in ovarian cancerpatients undergoing chemotherapy with cisplatin.

Tuesday, September 4, 2012

Ovarian cancer is difficult to detect, so listen to your body


Ovarian cancer is difficult to detect, so listen to your body


By Tara M. Ibarbo / For Healthy U

Sunday, September 2, 2012

Annette Mattern: What Every Woman Should Know About Ovarian Cancer

Annette Mattern: What Every Woman Should Know About Ovarian Cancer


Annette Mattern: What Every Woman Should Know About Ovarian Cancer

“How do I know if I have ovarian cancer?” the question most asked by women about the disease that, for years, was called the silent killer. Ovarian cancer is the fifth leading cause of cancer-related death among U.S. women and yet, most women know very little about it.

What you should know:
1. Every woman is at risk.

2. One is 72 women will develop ovarian cancer; one in 95 women will die from it.

3. Increased risk factors:
• Personal history of breast cancer
• Family history of breast or ovarian cancer.
• BRCA1 or BRCA2 genes, responsible for 5-10% of ovarian cancers. Women of Ashkenazi Jewish descent are at higher risk of carrying these mutations.

4. There is no screening tool, not even the PAP, so it is critical that women recognize the symptoms as early as possible.
• Stage I recurrence rate is only 10%.
• Stage III or IV (about 75% of cases) recur 85-95% of the time. Their 5-year survival rate is only 46%.

5. 95% of women with ovarian cancer experience symptoms, 90% at early stage. Symptoms:
• Bloating
• Pelvic or abdominal pain
• Difficulty eating or feeling full too quickly
• Urinary urgency or frequency
Other symptoms: fatigue, indigestion, back pain, pain with intercourse, constipation and menstrual irregularities.

What you should do:
If you exhibit persistent symptoms for more than a few weeks and this is not normal for your body, see a gynecologist. Your exam may include a CA-125 blood test, pelvic exam, and a trans-vaginal ultrasound. The only conclusive way to determine if it is cancer is by performing a biopsy.

Help spread the word.
Most women with ovarian cancer were misdiagnosed for years while their cancer spread. An earlier diagnosis is a woman’s best hope for a good prognosis.

Bio notes:
Annette Mattern is a 21-year survivor of ovarian cancer and recently survived breast cancer. She is the founder and president of the Ovarian Cancer Alliance of Arizona and serves on the board of directors of the Ovarian Cancer National Alliance. Her book on survival, Outside The Lines of Love, Life, and Cancer, is available on www.amazon.com.

Links: www.ocaz.org
www.ovariancancer.org